Cancer thrombosis: Narrative review
Venous thromboembolism (VTE) is a common disease in patients with cancer and carries a poor prognosis. Although the exact incidence of VTE in patients with cancer lies between 10% and 40%, it is prevalent in a substantial number of patients, either before starting treatment or during the treatment....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Cancer Research, Statistics, and Treatment |
| Subjects: | |
| Online Access: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2020;volume=3;issue=3;spage=501;epage=516;aulast=Munot |
| _version_ | 1818315716311384064 |
|---|---|
| author | Pritesh Naresh Munot Vanita Noronha Vijay Patil Amit Joshi Nandini Menon Kumar Prabhash |
| author_facet | Pritesh Naresh Munot Vanita Noronha Vijay Patil Amit Joshi Nandini Menon Kumar Prabhash |
| author_sort | Pritesh Naresh Munot |
| collection | DOAJ |
| description | Venous thromboembolism (VTE) is a common disease in patients with cancer and carries a poor prognosis. Although the exact incidence of VTE in patients with cancer lies between 10% and 40%, it is prevalent in a substantial number of patients, either before starting treatment or during the treatment. Vitamin K antagonists have been traditionally used as the preferred agents for the treatment of VTE. However, multiple studies have revealed that low-molecular-weight heparin (LMWH) is a better alternative for controlling and treating the thrombotic process. Direct oral anticoagulants (DOACs) have aroused considerable interest ever since their introduction. Despite the higher risk of bleeding associated with DOACs, patients prefer taking an oral tablet over parenteral therapy. The data from direct comparative studies are slowly emerging but are currently in favor of LMWH as compared to DOACs. However, in certain scenarios, such as renal failure and thrombocytopenia, other drugs should be considered before prescribing LMWH. Here, we have tried to analyze the current treatment strategy for cancer-associated thrombosis by reviewing articles, studies, and the guidelines based on them. We searched in MEDLINE for articles related to thrombosis and anticoagulation in patients with cancer, published between January 2000 and May 2020, with the full text available in the English language. |
| first_indexed | 2024-12-13T09:09:57Z |
| format | Article |
| id | doaj.art-1b5c8f08f7a0467abb999c7897625f61 |
| institution | Directory Open Access Journal |
| issn | 2590-3233 2590-3225 |
| language | English |
| last_indexed | 2024-12-13T09:09:57Z |
| publishDate | 2020-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Cancer Research, Statistics, and Treatment |
| spelling | doaj.art-1b5c8f08f7a0467abb999c7897625f612022-12-21T23:52:57ZengWolters Kluwer Medknow PublicationsCancer Research, Statistics, and Treatment2590-32332590-32252020-01-013350151610.4103/CRST.CRST_18_20Cancer thrombosis: Narrative reviewPritesh Naresh MunotVanita NoronhaVijay PatilAmit JoshiNandini MenonKumar PrabhashVenous thromboembolism (VTE) is a common disease in patients with cancer and carries a poor prognosis. Although the exact incidence of VTE in patients with cancer lies between 10% and 40%, it is prevalent in a substantial number of patients, either before starting treatment or during the treatment. Vitamin K antagonists have been traditionally used as the preferred agents for the treatment of VTE. However, multiple studies have revealed that low-molecular-weight heparin (LMWH) is a better alternative for controlling and treating the thrombotic process. Direct oral anticoagulants (DOACs) have aroused considerable interest ever since their introduction. Despite the higher risk of bleeding associated with DOACs, patients prefer taking an oral tablet over parenteral therapy. The data from direct comparative studies are slowly emerging but are currently in favor of LMWH as compared to DOACs. However, in certain scenarios, such as renal failure and thrombocytopenia, other drugs should be considered before prescribing LMWH. Here, we have tried to analyze the current treatment strategy for cancer-associated thrombosis by reviewing articles, studies, and the guidelines based on them. We searched in MEDLINE for articles related to thrombosis and anticoagulation in patients with cancer, published between January 2000 and May 2020, with the full text available in the English language.http://www.crstonline.com/article.asp?issn=2590-3233;year=2020;volume=3;issue=3;spage=501;epage=516;aulast=Munotcancer-associated thrombosisdirect oral anticoagulantslow-molecular-weight heparinvitamin k antagonists |
| spellingShingle | Pritesh Naresh Munot Vanita Noronha Vijay Patil Amit Joshi Nandini Menon Kumar Prabhash Cancer thrombosis: Narrative review Cancer Research, Statistics, and Treatment cancer-associated thrombosis direct oral anticoagulants low-molecular-weight heparin vitamin k antagonists |
| title | Cancer thrombosis: Narrative review |
| title_full | Cancer thrombosis: Narrative review |
| title_fullStr | Cancer thrombosis: Narrative review |
| title_full_unstemmed | Cancer thrombosis: Narrative review |
| title_short | Cancer thrombosis: Narrative review |
| title_sort | cancer thrombosis narrative review |
| topic | cancer-associated thrombosis direct oral anticoagulants low-molecular-weight heparin vitamin k antagonists |
| url | http://www.crstonline.com/article.asp?issn=2590-3233;year=2020;volume=3;issue=3;spage=501;epage=516;aulast=Munot |
| work_keys_str_mv | AT priteshnareshmunot cancerthrombosisnarrativereview AT vanitanoronha cancerthrombosisnarrativereview AT vijaypatil cancerthrombosisnarrativereview AT amitjoshi cancerthrombosisnarrativereview AT nandinimenon cancerthrombosisnarrativereview AT kumarprabhash cancerthrombosisnarrativereview |